GMM vs KALA Comparison

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital asset development for the metaverse industry. The Company leverages its proprietary Mofy Lab technology platform, which integrates three-dimensional (3D) reconstruction technology and artificial intelligence (AI) interactive technology, to create high-definition virtual versions of physical world objects, including humans, animals, and scenes. It provides comprehensive technology solutions to support virtual content production for use across movies, television series, animation, advertising, and gaming. The Company operates through Virtual Technology Services, which generates the majority of revenue, and Digital Asset Development and others.

Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.